Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
29.47%
Operating Margin
25.04%
Net Margin
5.76%
Efficiency Metrics
Revenue per Expense Ratio
1.33
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
25.41%
Income Tax Rate
1.61%
EPS
0.3200000000
Balance Sheet Analysis
Current Ratio
19.64
Cash Ratio
16.01
Working Capital
$601.66M
Debt to Equity
1.00
Debt to Assets
47.64%
Equity Ratio
47.50%
Cash Flow Analysis
Operating Cash Flow Ratio
23.77%
Free Cash Flow Ratio
13.79%
CapEx to Revenue
9.98%
Dividends Paid
$74.31M
Stock Buybacks
$80.37M
Total Shareholder Returns
$154.68M
Cash Position Change
3.53%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 100.97%
Detailed Growth Metrics
Core Performance
Revenue
11.05%
Net Income
82.24%
EPS
23.08%
Operating Income
144.81%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
4.74%
Operating Cash Flow
22.85%
Free Cash Flow
138.32%
Balance Sheet Health
Assets
-1.18%
Debt
0.38%
Book Value per Share
0.53%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
100.97%
Shares Outstanding
-3.72%
Long Term Trends
3Y Revenue/Share
195.61%
5Y Revenue/Share
-15.90%
3Y Dividend/Share
-8.97%
5Y Dividend/Share
-67.79%